Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 2/20 | 0.48 |
| ▸ | MTAP | Q13126 | 7/20 | 0.47 |
| ▸ | PNP | P00491 | 10/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505499 | 0.90 | HPRT1 (0.50) | HPRT1MTAPPNP | |
| SCHEMBL505494 | 0.89 | MTAP (0.45) | HPRT1MTAPPNP | |
| SCHEMBL505684 | 0.85 | MTAP (0.59) | HPRT1MTAPPNP | |
| SCHEMBL5606739 | 0.83 | PNP (0.60) | HPRT1MTAPPNP | |
| SCHEMBL506019 | 0.83 | PNP (0.60) | HPRT1MTAPPNP | |
| SCHEMBL7100238 | 0.83 | PNP (0.60) | HPRT1MTAPPNP | |
| Hydrochloric Acid SCHEMBL4065724 | 0.82 | PNP (0.59) | HPRT1MTAPPNP | |
| SCHEMBL505834 | 0.78 | PNP (0.55) | HPRT1MTAPPNP | |
| SCHEMBL506137 | 0.74 | PNP (0.40) | PNP | |
| SCHEMBL6250470 | 0.74 | PNP (0.37) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | claimed |
| US-20030114466-A1 | Inhibiting T-cell proliferation | BIOCRYST PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | claimed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050250728-A1 | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof | BIOCRYST PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-6660719-B2 | Inhibiting T-Cell proliferation | BIOCRYST PHARMACEUTICALS INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030114466-A1 | Inhibiting T-cell proliferation | BIOCRYST PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | HPRT1 124/4885MTAP 1119/4885PNP 35/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | HPRT1 6/4885MTAP 34/4885PNP 1/4885 |
| US-20030114466-A1 | Inhibiting T-cell proliferation | PNP, TYMP, ENTPD5 | HPRT1 40/4885MTAP 7/4885PNP 1/4885 |
| US-20050250728-A1 | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof | PNP, UNG, TYMP | HPRT1 17/4885MTAP 5/4885PNP 1/4885 |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | HPRT1 124/4885MTAP 1119/4885PNP 35/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | HPRT1 114/4885MTAP 1036/4885PNP 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.